抗体和α-synuclein:什么是针对帕金森病的目标?
1Interdisciplinary Nanoscience Centre (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, DK - 8000, Aarhus, Denmark.
Biochimica et biophysica acta. Proteins and proteomics
|October 2, 2023
概括
在帕金森病 (PD) 中准α-synuclein (α-syn) 聚合面临各种聚合物的挑战. 了解抗体与α-syn聚合物的相互作用对于有效的临床试验至关重要.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质生物化学 蛋白质生物化学
- 免疫学 免疫学 免疫学
背景情况:
- 帕金森病 (PD) 的特点是α-syn蛋白聚合.
- 不同的α-syn聚合物类型 (寡合体与纤维状) 的细胞毒性仍然不清楚.
- 以前针对α-syn的PD基于抗体的临床试验取得了令人失望的结果.
研究的目的:
- 审查针对PD治疗α-syn聚合的挑战.
- 评估当前对抗α-syn聚合物的抗体的理解.
- 确定改善基于抗体的PD疗法的需求.
主要方法:
- 审查关于α-syn聚合和抗体开发的现有文献.
- 对α-syn向抗体的临床试验结果的分析.
- 对研究α-syn聚合物的新型微流体技术的讨论.
主要成果:
- 多个α-syn聚合物的形成使治疗策略复杂化.
- 对抗α-syn聚合物的抗体机制缺乏彻底的了解,阻碍了临床成功.
- 目前的抗体研究往往缺乏标准化,阻碍了进展.
结论:
- 对α-syn聚合物特性和抗体相互作用的更深入的理解对于PD治疗的发展至关重要.
- 需要进行标准化抗体研究和先进的技术,如微流体学.
- 未来的临床试验需要在分子洞察力方面建立更强大的基础,以实现有效性.
相关概念视频
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


